Free Trial
NASDAQ:IMA

ImageneBio Q3 2024 Earnings Report

ImageneBio logo
$8.15 +0.45 (+5.84%)
As of 04:00 PM Eastern

ImageneBio EPS Results

Actual EPS
-$2.28
Consensus EPS
-$3.24
Beat/Miss
Beat by +$0.96
One Year Ago EPS
N/A

ImageneBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImageneBio Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
8:00AM ET

Earnings Documents

ImageneBio Earnings Headlines

ImageneBio (IMA) & Its Competitors Head to Head Review
Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to Hold
What The Silver Boom Could Mean For You…
AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-overlooked metal isn’t just about “green tech” anymore — it’s becoming critical to the AI revolution and modern energy systems. A new report explains why silver may be one of the most undervalued assets in the market today, and how everyday investors can use it to diversify and protect their savings. It also outlines a simple IRS-approved strategy that makes owning silver easier than most people realize.tc pixel
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA), a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

View ImageneBio Profile

More Earnings Resources from MarketBeat